IL17A and colorectal carcinoma: While beyond the scope of this work, future studies that disrupt IL-17 signaling, through genetic modification or neutralizing antibodies, in the F. nucleatum preclinical models we have developed herein could begin to unravel the importance of IL-17 signaling for F. nucleatum-positive human CRC.